Skip to content

Effect of Glaucoma medications

Correlation of Ocular Surface Disease Index and Quality of Life in Medically Treated Glaucoma Patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2017/12/011044
Enrollment
110
Registered
2017-12-29
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Glaucoma

Interventions

Intervention1: Antiglaucoma Medications without Preservatives: Antiglaucoma Medications without Preservatives Control Intervention1: Antiglaucoma Medications with Preservatives: Antiglaucoma Medicatio

Sponsors

Government Medical College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients of Primary Open Angle Glaucoma, Ocular Hypertension, Pseudoexfoliative glacauma, Pigment Dispersion Syndrome, Normal Tension Glaucoma. 2.Age group more than 40 years old 3.Patients who are on anti-glaucoma medication for at least three months.

Exclusion criteria

Exclusion criteria: 1.Patients with pre exisiting ocular surface disease prior to institution of medical therapy. 2.Patients with cognitive, hearing and mobility impairments. 3.Corneal abnormalities, or other conditions preventing reliable applanation tonometry; prior refractive eye surgery; prior filtration surgery. 4.Hypersensitivity or contraindication to use of Prostaglandins 5.Pregnant or lactating females. 6.Patients with other visually significant diseases like visually significant cataract, diabetic retinopathy, diabetic maculopathy, hypertensive retinopathy, age related macular degeneration (ARMD).

Design outcomes

Primary

MeasureTime frame
1. Ocular Surface Disease Score using OSDI Questionnaire 2.Quality of Life (QoL) using GQL-15 Questionnaire Timepoint: At Primary Visit

Secondary

MeasureTime frame
1. Visual Acuity of 6 meters. 2. IOP using Goldman Applanation Tonometer (GAT) 3. MD and PSD using Humphrey field analyzer HFA-,24-2 SITA Fast visual field. 4. Central Corneal Thickness (CCT) using pachymeter.Timepoint: At Primary Visit

Countries

India

Contacts

Public ContactSanchi Vohra

Government Medical College and Hospital

drsuresh.kumar.gupta@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026